NCT01228760 (Clinical Trial/ ASG-5ME)

Study Title
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer (NCT01228760)

Trial Description
The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC). This trial is sponsored by Astellas. [1]

Study Data

  • Condition: Prostate Cancer
  • Interventions:
    • Drugs used in this trial
      • ASG5ME
  • Phase: I
  • Enrollment: 46
  • Start: October 2010
  • Completion: February 2013
  • Last verified: June 2013

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.